Acumen Pharmaceuticals targets late 2026 for Phase II ALTITUDE-AD trial results and mid-2027 for IND submissions for two EBD candidates.
Acumen Pharmaceuticals plans to release top-line data from its Phase II ALTITUDE-AD trial of sabirnetug in late 2026. The company also aims to file Investigational New Drug applications for two additional early-stage candidates by mid-2027.
The ALTITUDE-AD trial has progressed through Q1 2026, building on clinical momentum from the past year. Sabirnetug is being evaluated for its potential in treating Alzheimer’s disease-related conditions.
No immediate market reaction was disclosed in the earnings call update.